Skip to main content
Erschienen in: Allergo Journal 8/2017

07.12.2017 | Original

Technical specifications of the Global Allergy and Asthma European Network (GA2LEN) chamber: a novel mobile allergen exposure chamber

verfasst von: Torsten Voegler, Frank Goergen, Karl-Christian Bergmann, Georg Boelke, Joseph Salame, Julia Gildemeister, Prof. Dr. Torsten Zuberbier

Erschienen in: Allergo Journal | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Field trials are the traditional approach for clinical trials in allergy but are under criticism for lack of standardization as they are affected by uncontrollable parameters such as environmental conditions, pollen counts, or lifestyle. Stationary allergen exposure chambers with a defined concentration of allergens under stable and standardized environmental conditions have been used to overcome these restrictions but have not allowed multicenter studies. We here describe the technical specifications and validation of a novel mobile pollen chamber specifically designed for multicenter studies — the GA2LEN chamber.

Methods

Two inter-connectable standard-sized container frames were used as a structural basis for the newly developed allergen exposure chamber. One container accommodates an observation room, also used as an office, and a changing room. The other container houses the test chamber itself and the technical installations. A customized air condition system was integrated and several environmental sensors were installed in the test chamber. Environmental tests have been performed at various outside conditions. The airflow in the test chamber was designed to prevent unspecific symptoms. To allow for an individual particle exposure at each seat, a new particle disperse and distribution system was developed, patented and validated.

Results

Technical and clinical validation tests have been successfully performed with Phleum pratense, Betula pendula, and mixtures of Dermatophagoides farinae, and Dermatophagoides pteronyssinus. The newly developed particle disperse system enable individual verum and placebo exposure, an even particle distribution at every seating position. The built-in air-conditioner is able to generate a tightly controlled, standardized and comfortable environment and the airflow did not provoke clinically significant irritation to lower respiratory tract, nose, or eyes. The chamber transportation has proven to be flexible and cost-effective.

Conclusion

The GA2LEN chamber provides a novel mobile exposure chamber technology for research and clinical trials allowing a fast, affordable, and standardized multicenter approach.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Pawankar R, Canonica GW, ST Holgate ST, Lockey RF, Blaiss M. World Allergy Organization (WAO) White Book on Allergy: Update 2013 Pawankar R, Canonica GW, ST Holgate ST, Lockey RF, Blaiss M. World Allergy Organization (WAO) White Book on Allergy: Update 2013
2.
Zurück zum Zitat Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol 2011;106:12–6CrossRef Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol 2011;106:12–6CrossRef
3.
Zurück zum Zitat Small M, Piercy J, Demoly P, Marsden H. Burden of illness and quality of life in patients being treated for seasonal allergic rhinitis: a cohort survey. Clin Transl Allergy 2013;3:33 Small M, Piercy J, Demoly P, Marsden H. Burden of illness and quality of life in patients being treated for seasonal allergic rhinitis: a cohort survey. Clin Transl Allergy 2013;3:33
4.
Zurück zum Zitat D’Amato G, Cecchi L, D’Amato M, Liccardi G. Urban Air Pollution and Climate Change as Environmental Risk Factors of Respiratory Allergy: An Update. J Investig Allergol Clin Immunol 2010;20:95–102PubMed D’Amato G, Cecchi L, D’Amato M, Liccardi G. Urban Air Pollution and Climate Change as Environmental Risk Factors of Respiratory Allergy: An Update. J Investig Allergol Clin Immunol 2010;20:95–102PubMed
5.
Zurück zum Zitat Jacobs RL, Harper N, He W, Andrews CP, Rather CG, Ramirez DA, et al. Effect of confounding cofactors on responses to pollens during natural season versus pollen challenge chamber exposure. J Allergy Clin Immunol 2014;133:1340–6CrossRef Jacobs RL, Harper N, He W, Andrews CP, Rather CG, Ramirez DA, et al. Effect of confounding cofactors on responses to pollens during natural season versus pollen challenge chamber exposure. J Allergy Clin Immunol 2014;133:1340–6CrossRef
6.
Zurück zum Zitat Day JH, Horak F, Briscoe MP, Canonica GW, Fineman SM, Krug N, et al. The role of allergen challenge chambers in the evaluation of anti-allergic medication: an international consensus paper. Clin Exp Allergy Rev 2006;6:31–59CrossRef Day JH, Horak F, Briscoe MP, Canonica GW, Fineman SM, Krug N, et al. The role of allergen challenge chambers in the evaluation of anti-allergic medication: an international consensus paper. Clin Exp Allergy Rev 2006;6:31–59CrossRef
7.
Zurück zum Zitat Rösner-Friese K, Kaul S, Vieths S, Pfaar O. Environmental exposure chambers in allergen immunotherapy trials: Current status and clinical validation needs. J Allergy Clin Immunol 2015;135:636–43CrossRef Rösner-Friese K, Kaul S, Vieths S, Pfaar O. Environmental exposure chambers in allergen immunotherapy trials: Current status and clinical validation needs. J Allergy Clin Immunol 2015;135:636–43CrossRef
8.
Zurück zum Zitat Werchan B, Werchan M, Mücke HG, Gauger U, Simoleit A, Zuberbier T, Bergmann KC. Spatial distribution of allergenic pollen through a large metropolitan area. Environ Monit Assess. 2017;189:169CrossRef Werchan B, Werchan M, Mücke HG, Gauger U, Simoleit A, Zuberbier T, Bergmann KC. Spatial distribution of allergenic pollen through a large metropolitan area. Environ Monit Assess. 2017;189:169CrossRef
9.
Zurück zum Zitat Bastl K, Kmenta M, Jäger S, Bergmann KC, Berger U. European Aeroallergen Network: Development of a symptom load index: enabling temporal and regional pollen season comparisons and pointing out the need for personalized pollen information. Aerobiologia 2014;30:269–80CrossRef Bastl K, Kmenta M, Jäger S, Bergmann KC, Berger U. European Aeroallergen Network: Development of a symptom load index: enabling temporal and regional pollen season comparisons and pointing out the need for personalized pollen information. Aerobiologia 2014;30:269–80CrossRef
10.
Zurück zum Zitat Simoleit S, Gauger U, Mücke HG, Werchan M, Obstova B, Zuberbier T, Bergmann KC. Intradiurnal patterns of allergenic airborne pollen near a city motorway in Berlin, Germany. Aerobiologia 2016;32:199–209CrossRef Simoleit S, Gauger U, Mücke HG, Werchan M, Obstova B, Zuberbier T, Bergmann KC. Intradiurnal patterns of allergenic airborne pollen near a city motorway in Berlin, Germany. Aerobiologia 2016;32:199–209CrossRef
11.
Zurück zum Zitat Bernstein JA. Correlation between a pollen challenge chamber and a natural allergen exposure study design for eliciting ocular and nasal symptoms: earl evidence supporting a paradigm shift in drug investigation? J Allergy Clin Immunol 2012;130:128–9CrossRef Bernstein JA. Correlation between a pollen challenge chamber and a natural allergen exposure study design for eliciting ocular and nasal symptoms: earl evidence supporting a paradigm shift in drug investigation? J Allergy Clin Immunol 2012;130:128–9CrossRef
12.
Zurück zum Zitat Badorrek P, Dick M, Hecker H, Schaumann F, Sousa AR, Murdoch R, et al. Anti-allergic drug testing in an environmental challenge chamber is suitable both in and out of the relevant pollen season. Ann Allergy Asthma Immunol 2011;106:336–41CrossRef Badorrek P, Dick M, Hecker H, Schaumann F, Sousa AR, Murdoch R, et al. Anti-allergic drug testing in an environmental challenge chamber is suitable both in and out of the relevant pollen season. Ann Allergy Asthma Immunol 2011;106:336–41CrossRef
13.
Zurück zum Zitat Devillier P, Le Gall M, Horak F. The allergen challenge chamber: a valuable tool for optimizing the clinical development of pollen immunotherapy. Allergy 2011;66:163–9CrossRef Devillier P, Le Gall M, Horak F. The allergen challenge chamber: a valuable tool for optimizing the clinical development of pollen immunotherapy. Allergy 2011;66:163–9CrossRef
14.
Zurück zum Zitat Horak F, Jäger S. Die Wiener Provokations-Kammer (Vienna Challenge Chamber). Eine neue Methode des Allergenexpositionstests. Wien Klin Wochenschr 1987;99:509–10 Horak F, Jäger S. Die Wiener Provokations-Kammer (Vienna Challenge Chamber). Eine neue Methode des Allergenexpositionstests. Wien Klin Wochenschr 1987;99:509–10
15.
Zurück zum Zitat Krug N, Hohlfeld JM, Larbig M, Buckendahl A, Badorrek P, Geldmacher H, et al. Validation of an environmental exposure unit for controlled human inhalation studies with grass pollen in patients with seasonal allergic rhinitis. Clin Exp Allergy 2003;33:1667–74CrossRef Krug N, Hohlfeld JM, Larbig M, Buckendahl A, Badorrek P, Geldmacher H, et al. Validation of an environmental exposure unit for controlled human inhalation studies with grass pollen in patients with seasonal allergic rhinitis. Clin Exp Allergy 2003;33:1667–74CrossRef
16.
Zurück zum Zitat Del Cuvillo A, Sastre J, Bartra J, Mullol J, DaVila I, Montoro J, et al. Placebo effect in clinical trials involving patients with allergic rhinitis. J Investig Allergol Clin Immunol 2011;21:40–5PubMed Del Cuvillo A, Sastre J, Bartra J, Mullol J, DaVila I, Montoro J, et al. Placebo effect in clinical trials involving patients with allergic rhinitis. J Investig Allergol Clin Immunol 2011;21:40–5PubMed
17.
Zurück zum Zitat Pfaar O, Calderon MA, Andrews CP, Angjeli E, Bergmann KC, Bønløkke JH, et al. Allergen Exposure Chambers (AEC): harmonizing current concepts and projecting the needs for the future - an EAACI Position Paper. Allergy 2017;72:1035–42CrossRef Pfaar O, Calderon MA, Andrews CP, Angjeli E, Bergmann KC, Bønløkke JH, et al. Allergen Exposure Chambers (AEC): harmonizing current concepts and projecting the needs for the future - an EAACI Position Paper. Allergy 2017;72:1035–42CrossRef
18.
Zurück zum Zitat Goergen, F, Sehlinger, T. Method and device for controlled emission of particles, EU Patent EP3058866, 27.07.2015 Goergen, F, Sehlinger, T. Method and device for controlled emission of particles, EU Patent EP3058866, 27.07.2015
19.
Zurück zum Zitat Goergen, F, Sehlinger, T. Method and device for controlled emission of particles, EU Patent EP3020435, 09.07.2015 Goergen, F, Sehlinger, T. Method and device for controlled emission of particles, EU Patent EP3020435, 09.07.2015
20.
Zurück zum Zitat King EM, Filep S, Smith B, Duncan R, Block D, Armstrong J, Chapman MD. Quality Control Procedures using Multiplex Array for Indoor Allergens in an Analytical Laboratory. European Journal of Allergy and Clinical Immunology 2010;65:98 King EM, Filep S, Smith B, Duncan R, Block D, Armstrong J, Chapman MD. Quality Control Procedures using Multiplex Array for Indoor Allergens in an Analytical Laboratory. European Journal of Allergy and Clinical Immunology 2010;65:98
21.
Zurück zum Zitat Zuberbier T, Abelson MB, Akdis CA, Bachert C, Berger U, Bindslev-Jensen C, et al. for the GA2LEN EU Network of Excellence in Allergy and Asthma. Validation of the Global Allergy and Asthma European Network (GA2LEN) Chamber for Trials in Allergy: Innovation of a Mobile Allergen Exposure Chamber. J Allergy Clin Immunol 2017;139:1158–66CrossRef Zuberbier T, Abelson MB, Akdis CA, Bachert C, Berger U, Bindslev-Jensen C, et al. for the GA2LEN EU Network of Excellence in Allergy and Asthma. Validation of the Global Allergy and Asthma European Network (GA2LEN) Chamber for Trials in Allergy: Innovation of a Mobile Allergen Exposure Chamber. J Allergy Clin Immunol 2017;139:1158–66CrossRef
22.
Zurück zum Zitat Patel P, Nandkeshore H, Shields K. Mobile Natural Exposure Chamber Technology Standardizes Controlled Environmental Exposure Chamber Challenges Across Multicenter National and International Allergy Trials. J Allergy Clin Immunol 2013;131:AB188 Patel P, Nandkeshore H, Shields K. Mobile Natural Exposure Chamber Technology Standardizes Controlled Environmental Exposure Chamber Challenges Across Multicenter National and International Allergy Trials. J Allergy Clin Immunol 2013;131:AB188
23.
Zurück zum Zitat Jacobs RL, Ramirez DA, Andrews CP. Validation of the Biogenics Research Chamber for Juniperus ashei (mountain cedar) pollen. Ann Allergy Asthma Immunol. 2011;107:133–8CrossRef Jacobs RL, Ramirez DA, Andrews CP. Validation of the Biogenics Research Chamber for Juniperus ashei (mountain cedar) pollen. Ann Allergy Asthma Immunol. 2011;107:133–8CrossRef
24.
Zurück zum Zitat Ito K, Terada T, Yuki A, Ichihara T, Hyo S, Kawata R, et al. Preliminary study of a challenge test to the patients with Japanese cedar pollinosis using an environmental exposure unit. Auris Nasus Larynx 2010; 37:694–9CrossRef Ito K, Terada T, Yuki A, Ichihara T, Hyo S, Kawata R, et al. Preliminary study of a challenge test to the patients with Japanese cedar pollinosis using an environmental exposure unit. Auris Nasus Larynx 2010; 37:694–9CrossRef
25.
Zurück zum Zitat Hamasaki S, Okamoto Y, Yonekura S, Okuma Y, Sakurai T, Iinuma T, et al. Characteristics of the Chiba Environmental Challenge Chamber. Allergology International 2014;63:41–50CrossRef Hamasaki S, Okamoto Y, Yonekura S, Okuma Y, Sakurai T, Iinuma T, et al. Characteristics of the Chiba Environmental Challenge Chamber. Allergology International 2014;63:41–50CrossRef
26.
Zurück zum Zitat Jacobs RL, Andrews CP, Ramirez DA, Rather CG, Harper N, Jimenez F, et al. Symptom dynamics during repeated serial allergen challenge chamber exposures to house dust mite. Allergy Clin Immunol 2015;135:1071–5CrossRef Jacobs RL, Andrews CP, Ramirez DA, Rather CG, Harper N, Jimenez F, et al. Symptom dynamics during repeated serial allergen challenge chamber exposures to house dust mite. Allergy Clin Immunol 2015;135:1071–5CrossRef
Metadaten
Titel
Technical specifications of the Global Allergy and Asthma European Network (GA2LEN) chamber: a novel mobile allergen exposure chamber
verfasst von
Torsten Voegler
Frank Goergen
Karl-Christian Bergmann
Georg Boelke
Joseph Salame
Julia Gildemeister
Prof. Dr. Torsten Zuberbier
Publikationsdatum
07.12.2017
Verlag
Springer Medizin
Erschienen in
Allergo Journal / Ausgabe 8/2017
Print ISSN: 0941-8849
Elektronische ISSN: 2195-6405
DOI
https://doi.org/10.1007/s15007-017-1495-5

Weitere Artikel der Ausgabe 8/2017

Allergo Journal 8/2017 Zur Ausgabe

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.